Skip to main content
Log in

Southern copperhead venom enhances tissue-type plasminogen activator induced fibrinolysis but does not directly lyse human plasma thrombi

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

In addition to degrading fibrinogen as a source of consumptive coagulopathy, purified fractions of southern copperhead (Agkistrodon contortrix contortrix; A. c. contortrix) venom has been demonstrated to enhance fibrinolysis. The goal of this investigation was to characterize the kinetic fibrinolytic profile of A. c. contortrix venom in the absence and presence of tissue-type plasminogen activator (tPA) to determine if intact venom had tPA independent fibrinolytic properties. Utilizing thrombelastographic methods, the coagulation and fibrinolytic kinetic profiles of human plasma exposed to A. c. contortrix venom (0–6 μg/ml) were determined in the absence or presence of tPA (0–100 IU/ml). Then, plasma was exposed to 0–6 μg/ml of venom without tPA added and coagulation observed for 3 h. Venom significantly prolonged the onset of coagulation, decreased the velocity of thrombus growth but did not significantly decrease clot strength. In the presence of tPA, venom significantly decreased clot strength, shortened the time of onset of fibrinolysis, decreased clot lysis time but did not significantly affect the maximum rate of lysis. Lastly, while venom exposure in the absence of tPA significantly prolonged the onset of coagulation and decreased the velocity of clot growth, venom exposure did not result in detectable fibrinolysis over the 3 h observation period. A. c. contortrix venom enhances tPA mediated fibrinolysis by degrading plasma coagulation kinetics. Intact A. c. contortrix venom does not possess sufficient fibrinolytic activity to cause fibrinolysis in human plasma at the concentration tested.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. McCleary RJ, Kini RM (2013) Snake bites and hemostasis/thrombosis. Thromb Res 132:642–646

    Article  CAS  PubMed  Google Scholar 

  2. Markland FS Jr, Swenson S (2013) Snake venom metalloproteinases. Toxicon 62:3–18

    Article  CAS  PubMed  Google Scholar 

  3. Bajwa SS, Kirakossian H, Reddy KN, Markland FS (1982) Thrombin-like and fibrinolytic enzymes in the venoms from the Gaboon viper (Bitis gabonica), eastern cottonmouth moccasin (Agkistrodon p. piscivorus) and southern copperhead (Agkistrodon c. contortrix) snakes. Toxicon 20:427–432

    Article  CAS  PubMed  Google Scholar 

  4. Shimizu A, Jimenez EC, Takagi J, Inada Y, Saito Y (1987) Venom from southern copperhead snake (Agkistrodon contortrix contortrix). I. Characterization of a protease that preferentially releases fibrinopeptide B. Toxicon 25:751–757

    Article  CAS  PubMed  Google Scholar 

  5. Ramírez MS, Sánchez EE, García-Prieto C, Pérez JC, Chapa GR, McKeller MR, Ramírez R, De Anda Y (1999) Screening for fibrinolytic activity in eight Viperid venoms. Comp Biochem Physiol C 124:91–98

    PubMed  Google Scholar 

  6. Markland FS, Swenson S (2010) Fibrolase: trials and tribulations. Toxins (Basel) 2:793–808

    Article  CAS  Google Scholar 

  7. Aitchison JM (1990) Boomslang bite–diagnosis and management. A report of 2 cases. S Afr Med J 78:39–42

    CAS  PubMed  Google Scholar 

  8. Hadley GP, McGarr P, Mars M (1999) The role of thromboelastography in the management of children with snake-bite in southern Africa. Trans R Soc Trop Med Hyg 93:177–179

    Article  CAS  PubMed  Google Scholar 

  9. Nielsen VG, Cohen BM, Cohen E (2006) Elastic modulus-based thrombelastographic quantification of plasma clot fibrinolysis with progressive plasminogen activation. Blood Coagul Fibrinolysis 17:75–81

    Article  CAS  PubMed  Google Scholar 

  10. Sherman DG, Atkinson RP, Chippendale T, Levin KA, Ng K, Futrell N, Hsu CY, Levy DE (2000) Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial. Stroke treatment with ancrod trial. JAMA 283:2395–2403

    Article  CAS  PubMed  Google Scholar 

  11. Hennerici MG, Kay R, Bogousslavsky J, Lenzi GL, Verstraete M, Orgogozo JM, ESTAT investigators (2006) Intravenous ancrod for acute ischaemic stroke in the European Stroke Treatment with Ancrod Trial: a randomised controlled trial. Lancet 368:1871–1878

    Article  CAS  PubMed  Google Scholar 

  12. Levy DE, del Zoppo GJ, Demaerschalk BM, Demchuk AM, Diener HC, Howard G, Kaste M, Pancioli AM, Ringelstein EB, Spatareanu C, Wasiewski WW (2009) Ancrod in acute ischemic stroke: results of 500 subjects beginning treatment within 6 hours of stroke onset in the ancrod stroke program. Stroke 40:3796–3803

    Article  PubMed  Google Scholar 

Download references

Acknowledgment

This investigation was supported by the Department of Anesthesiology.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Vance G. Nielsen.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nielsen, V.G. Southern copperhead venom enhances tissue-type plasminogen activator induced fibrinolysis but does not directly lyse human plasma thrombi. J Thromb Thrombolysis 42, 33–37 (2016). https://doi.org/10.1007/s11239-015-1287-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-015-1287-2

Keywords

Navigation